Research Paper Volume 13, Issue 16 pp 20131—20148

Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells

Potential immune normalization using NKM-cell therapy in sub-healthy individuals. (A) The schedule of NKM-cell therapy for sub-healthy individuals. After physical examination, 20–30 ×108 NKM cells were used for each injection, and three injections were administered in one course of treatment, with a time interval of 1 month. Detection of the therapeutic effect during NKM-cell treatment was undertaken before the second injection. Detection of the final effect was undertaken 1 month after the end of NKM-cell treatment. (B–E) Efficacious NKM-cell therapy for immune normalization in four sub-healthy individuals. Patient Z (B), Patient M (C), Patient J (D) and Patient C (E) were recruited. Proportions of CD3+PD-1+ cells/PBMCs and CD3+CD8+PD-1+ cells/CD3+CD8+ cells were measured before (pre-), during (mid-) and after (post-) NKM-cell treatment. The P-values are shown.

Figure 7. Potential immune normalization using NKM-cell therapy in sub-healthy individuals. (A) The schedule of NKM-cell therapy for sub-healthy individuals. After physical examination, 20–30 ×108 NKM cells were used for each injection, and three injections were administered in one course of treatment, with a time interval of 1 month. Detection of the therapeutic effect during NKM-cell treatment was undertaken before the second injection. Detection of the final effect was undertaken 1 month after the end of NKM-cell treatment. (BE) Efficacious NKM-cell therapy for immune normalization in four sub-healthy individuals. Patient Z (B), Patient M (C), Patient J (D) and Patient C (E) were recruited. Proportions of CD3+PD-1+ cells/PBMCs and CD3+CD8+PD-1+ cells/CD3+CD8+ cells were measured before (pre-), during (mid-) and after (post-) NKM-cell treatment. The P-values are shown.